Institute of Pharmaceutics, College of Pharmaceutical Sciences, Zhejiang University, 866 Yuhangtang Road, Hangzhou 310058, Zhejiang, PR China.
Zhejiang Provincial Corps Hospital of Chinese People's Armed Police Forces, Jiaxing, Zhejiang, PR China.
Eur J Pharmacol. 2018 Mar 15;823:72-78. doi: 10.1016/j.ejphar.2018.01.018. Epub 2018 Feb 4.
To investigate the effects of Hydroxysafflor Yellow A (HSYA), which is derived from safflower, on the proliferation, migration and angiogenesis of cells in vitro and its potential efficacy in vivo when topically applied to a diabetic wound. Human umbilical vein endothelial cells (HUVECs) and mouse macrophage cells (RAW264.7) were used to evaluate angiogenesis and anti-inflammatory activities, respectively. The influence of HSYA on the wound scratch assay was investigated in keratinocytes. A splinted excisional wound model in rats with TIDM induced by streptozotocin was used to assess the effects of wound healing. Collagen disposition and secretion of vascular growth factors (VEGF) as well as transforming growth factor-β1 (TGF-β1) were evaluated by an ELISA assay and histological staining. The in vitro results showed that HSYA could significantly enhance both the neovascularization of HUVECs and the migration of keratinocytes. It showed the significant inhibitory effect on nitric oxide production, indicating the anti-inflammatory activity of HSYA. In vivo, the topical application of HSYA significantly enhanced the wound closure rate, and the time to complete wound closure was 17 days, whereas 30 days were needed with PBS treatment. Further, treatment with HSYA exhibited significant granulation tissue formation with higher collagen content, re-epithelialization and angiogenesis according to Masson's trichrome staining evaluation, VEGE and TGF-β1 ELISA measurement. In conclusion, HSYA application could be considered a promising therapeutic strategy for treating chronic non-healing diabetic foot ulcers.
为了研究红花黄色素 A(HSYA)对细胞体外增殖、迁移和血管生成的影响,以及其局部应用于糖尿病创面时的体内潜在疗效。我们使用人脐静脉内皮细胞(HUVECs)和小鼠巨噬细胞(RAW264.7)分别评估血管生成和抗炎活性。在角质形成细胞中研究了 HSYA 对伤口划痕试验的影响。采用链脲佐菌素诱导的 TIDM 大鼠夹板切除伤口模型评估伤口愈合的效果。通过 ELISA 检测和组织学染色评估胶原蛋白分布和血管生长因子(VEGF)以及转化生长因子-β1(TGF-β1)的分泌。体外结果表明,HSYA 可显著增强 HUVEC 的新生血管形成和角质形成细胞的迁移。它对一氧化氮的产生表现出显著的抑制作用,表明 HSYA 具有抗炎活性。在体内,HSYA 的局部应用显著提高了伤口闭合率,用 PBS 处理时需要 30 天才能完成伤口闭合,而用 HSYA 处理时仅需 17 天。此外,根据 Masson 三色染色评估、VEGF 和 TGF-β1 ELISA 测量,HSYA 治疗表现出明显的肉芽组织形成,具有更高的胶原蛋白含量、再上皮化和血管生成。总之,HSYA 的应用可以被认为是治疗慢性难愈性糖尿病足溃疡的一种有前途的治疗策略。